|Bid||61.60 x 100|
|Ask||61.99 x 100|
|Day's Range||62.50 - 62.90|
|52 Week Range||57.18 - 66.80|
|PE Ratio (TTM)||39.88|
|Earnings Date||Jul 28, 2017|
|Dividend & Yield||1.88 (3.00%)|
|1y Target Est||69.70|
Merck , known as MSD outside the United States and Canada, today announced that the pivotal phase 3 KEYNOTE-040 trial investigating KEYTRUDA® , the company’s anti-PD-1 therapy, in previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma did not meet its pre-specified primary endpoint of overall survival . The safety profile observed in KEYNOTE-040 was consistent ...
The days of high-priced knockoffs of biologic drugs are ending quickly.
Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its follow-on biologic version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus. Merck's copycat, if launched, would challenge Lantus as a cheaper alternative that could chip away at the drug's sales, which reached 5.71 billion euros ($6.6 billion) last year and represented over a sixth of Sanofi's total sales.